0000000001307749
AUTHOR
Christina Dimopoulou
SPARC experiments at the high-energy storage ring
The physics program of the SPARC collaboration at the Facility for Antiproton and Ion Research (FAIR) focuses on the study of collision phenomena in strong and even extreme electromagnetic fields and on the fundamental interactions between electrons and heavy nuclei up to bare uranium. Here we give a short overview on the challenging physics opportunities of the high-energy storage ring at FAIR for future experiments with heavy-ion beams at relativistic energies with particular emphasis on the basic beam properties to be expected.
Laser cooling of stored relativistic ion beams with large momentum spreads using a laser system with a wide scanning range
New results on laser cooling of stored, bunched, relativistic ion beams are presented. For the first time it has been possible to cool an ion beam with large momentum spread without initial electron cooling or scanning of the bunching frequency by using a single cw laser system.
Gender-, age- and time-dependent dosing of growth hormone in adults - real-world data from a decade of clinical practice in Germany.
We evaluated treatment patterns and gender-dependent dosing of growth hormone (GH) substitution in adults with GH deficiency (AGHD). Data on GH dose were collected (2003-2013) from 509 GH-treated patients (mean age: 48.9 years; 47% female) enroled in the observational German NordiWin study (NCT01543880). The impact of gender, age, treatment duration and calendar year on GH treatment patterns was evaluated by multiple regression analysis. Mean (SD) baseline GH dose (mg/day) was similar between females (0.25 [0.19] and males (0.24 [0.15]), but increased with treatment duration (at year 10, 0.55 [0.48] and 0.31 [0.09] in females and males, respectively), reflecting patient dose titration. GH d…
Gender-, age- and time-dependent dosing of growth hormone in adults – real-world data from a decade of clinical practice in Germany
We evaluated treatment patterns and gender-dependent dosing of growth hormone (GH) substitution in adults with GH deficiency (AGHD). Data on GH dose were collected (2003–2013) from 509 GH-treated patients (mean age: 48.9 years; 47% female) enroled in the observational German NordiWin study (NCT01543880). The impact of gender, age, treatment duration and calendar year on GH treatment patterns was evaluated by multiple regression analysis. Mean (SD) baseline GH dose (mg/day) was similar between females (0.25 [0.19] and males (0.24 [0.15]), but increased with treatment duration (at year 10, 0.55 [0.48] and 0.31 [0.09] in females and males, respectively), reflecting patient dose titration. GH d…